 Inclusion Criteria: Histologically proven invasive breast cancer T1-4N0-3M0, pre- or postmenopausal breast cancer patient treated with adjuvant chemotherapy or radiotherapy within 4 months or patient who has started adjuvant endocrine therapy antiestrogens, aromatase inhibitors, LHRH agonists, or combinations no later than 4 months earlier,age from 35 to 68 years,signed informed consent prior to beginning protocol specific procedures 